MedTrace Logo

Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects

NCT00926016 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2012-02-14

No results posted yet for this study

Summary

The purpose of this study is to determine if rosiglitazone, a medicine used to treat diabetes, improves response to anti-viral treatment.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Pioglitazone (Actos)

pioglitazone 45 mg a day

Sponsors & Collaborators

  • The Geneva Foundation

    collaborator OTHER

  • Brooke Army Medical Center

    lead FED

Principal Investigators

  • Stephen A Harrison, MD · Brooke Army Medical Center

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2010-03-31
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00926016 on ClinicalTrials.gov